**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 35-year-old man developed COVID-19 infection and severe depletion of T-lymphocyte following treatment with alemtuzumab for multiple sclerosis.

The man, was diagnosed with relapsing remitting multiple sclerosis (RRMS) in November 2018. Therefore, he received a first dose of IV alemtuzumab 12 mg/day for five days in December 2018 and second dose of IV alemtuzumab 12 mg/day for three days at the end of February 2020. Between the both doses, he did not have any clinical deterioration. In March 2020 examinations revealed stable underlying lesion. Prior to the second infusion his absolute lymphocyte count (ALC) was 960/mm^3^, one month following the infusion ALC decreased to 210/mm^3^. Two and a half months following the infusion, he had contact with his COVID-19 positive wife. Subsequently, he experienced dry cough and a nasopharyngeal swab was positive for SARS-CoV-2 infection. He developed mild fever, but his respiratory rate, sounds and oxygen saturation were normal. And blood test showed ALC of 680/mm^3^ with severely reduced major circulating T lymphocyte subsets (CD3+, CD4+ and CD8+). Mean CD3+ count was reduced by 88% from lower limit of normal (LLN) while CD4+ and CD8+ were 82% and 85% below the LLN, respectively. NK cells and B lymphocytes were in normal limits.

The man, was suggested to follow a voluntary quarantine. He stayed at home. Two weeks following the first swab, the second test was negative for SARS-CoV-2 infection and he was asymptomatic. His COVID-19 infection and severe depletion of T-lymphocyte was considered to be developed due to the alemtuzumab treatment.
